⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 1, 2024Journal of Cancer Research and TherapeuticsOpen Access

Sarcopenia as a prognostic factor in patients with hepatocellular carcinoma treated with transcatheter arterial chemoembolization plus sorafenib

Rujian Wang Ligang Wang Yutian Jiang Mei Dong Mei Li Ping Sun

View Full Paper

Ask AI

Bookmark

Share

Abstract

Loss of skeletal muscle volume is an important aspect of sarcopenia in hepatocellular carcinoma (HCC) patients treated by surgical resection, transcatheter arterial chemoembolization (TACE), or sorafenib.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Wang et al. (2024) studied this question.

synapsesocial.com/papers/68e5e2bab6db6435875774c7 https://doi.org/10.4103/jcrt.jcrt_2451_23

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Impact of pre-sarcopenia on outcomes of transarterial chemoembolization in unresectable hepatocellular carcinoma2024 · 2 citations
2Impact of Sarcopenia on the Survival of Patients with Hepatocellular Carcinoma Treated with Sorafenib2024 · 4 citations
3Impact of Sarcopenia and Serum Creatinine on Clinical Outcomes after Tace in Hepatocellular CarcinomaCohort Study · 2026
4Prognostic value of CT-defined sarcopenic obesity in hepatocellular carcinoma patients undergoing transarterial chemoembolizationcohort · 2026
5Effect of Sarcopenia on the Prognosis of Clinical Outcomes in Patients With Hepatocellular Carcinoma After Hepatic Resection2024 · 5 citations